Patents by Inventor Shouichi Hazama

Shouichi Hazama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYSTEM FOR PREDICTING DRUG EFFECTS AND ADVERSE EFFECTS AND PROGRAM FOR THE SAME
    Publication number: 20110288783
    Abstract: A drug effect-adverse effect prediction system includes a clinical data analysis table generating part, for each combination of genotypes relating to a drug effect or adverse effect, for generation of an analysis table for handling cases related to presence or absence of the drug effect or adverse effect. The system also includes a reliability analysis part, a discrimination formula generating part, a prediction part, and a discrimination formula optimizing part.
    Type: Application
    Filed: June 1, 2011
    Publication date: November 24, 2011
    Applicants: Toyo Kohan Co., Ltd., YAMAGUCHI UNIVERSITY
    Inventors: Masaaki Oka, Yoshihiko Hamamoto, Shouichi Hazama, Yusuke Fujita, Ryouichi Tsunedomi
  • Kits and method for determining the risk of adverse effects of irinotecan comprising hybridizing pairs of nucleic acid probes
    Patent number: 7943311
    Abstract: A method for determining the risk of adverse effects of irinotecan (CPT-11), a synthetic anticancer drug, by detecting polymorphisms in the TATA box within the promoter region of the UDP-glucuronosyl transferase gene. A kit for detecting the adverse effects of irinotecan containing at least one pair of nucleic acid probes.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: May 17, 2011
    Assignees: Toyo Kohan Co., Ltd., Yamaguchi University
    Inventors: Hiroshi Okamura, Naoko Nakazawa, Masaaki Oka, Shouichi Hazama
  • METHOD FOR DETERMINING RISK OF ADVERSE EFFECT OF IRINOTECAN AND KIT FOR IT
    Publication number: 20080153093
    Abstract: A method for determining the risk of adverse effects of irinotecan (CPT-11), a synthetic anticancer drug, by detecting polymorphisms in the TATA box within the promoter region of the UDP-glucuronosyl transferase gene. A kit for detecting the adverse effects of irinotecan containing at least one pair of nucleic acid probes.
    Type: Application
    Filed: September 18, 2007
    Publication date: June 26, 2008
    Applicants: Toyo Kohan Co., Ltd., YAMAGUCHI UNIVERSITY
    Inventors: Hiroshi Okamura, Naoka Nakazawa, Masaaki Oka, Shouichi Hazama